Reviews
23 July 2025
Early Access
The role of anifrolumab in reshaping the treatment landscape of extra-renal systemic lupus erythematosus
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
81
Views
8
Downloads
Authors
Objective. Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder that typically requires management with immunosuppressive and anti-inflammatory treatments. The 2023 guidelines of the European Alliance of Associations for Rheumatology now recommend lowering maintenance glucocorticoid doses to ≤5 mg/day to reduce long-term health risks, a decrease from the previous 7.5 mg/day threshold set in 2019. To help achieve these reduced doses, early initiation of biologic therapies is suggested, even before conventional immunosuppressants. Belimumab and anifrolumab, the biologics currently approved for SLE treatment, have shown greater efficacy than placebo in clinical trials and similar safety profiles, supporting their use in achieving remission and enabling glucocorticoid tapering or discontinuation. This review evaluates the role of biologics, especially anifrolumab, in treating extra-renal SLE in Italy, using clinical scenarios to illustrate situations where early anifrolumab therapy could be beneficial.
Methods. Hypothetical scenarios derived from clinical practice were examined to identify real-life contexts suitable for the early initiation of anifrolumab treatment.
Results. Anifrolumab represents an effective therapeutic option for various extra-renal SLE patients. These include those who have failed to achieve or maintain remission with standard care, have contraindications to conventional immunosuppressants, are glucocorticoid-dependent, or experience mucocutaneous and musculoskeletal manifestations. Anifrolumab also offers potential benefits for patients planning pregnancy by promoting remission or low disease activity.
Conclusions. Despite its recent approval and limited real-world evidence, anifrolumab has emerged as a promising therapeutic option for non-renal lupus. We hope this review will encourage further studies on the efficacy and safety of anifrolumab in real-life SLE patient cohorts.
Altmetrics
Downloads
Download data is not yet available.
Citations
Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 2021; 80: 14-25. DOI: https://doi.org/10.1136/annrheumdis-2020-218272
Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis 2023; 82: 999-1014. DOI: https://doi.org/10.1136/ard-2022-223741
Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 2019; 15: 30-48. DOI: https://doi.org/10.1038/s41584-018-0133-2
Katarzyna PB, Wiktor S, Ewa D, Piotr L. Current treatment of systemic lupus erythematosus: a clinician’s perspective. Rheumatol Int 2023; 43: 1395. DOI: https://doi.org/10.1007/s00296-023-05306-5
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024; 83: 15-29. DOI: https://doi.org/10.1136/ard-2024-225617
Petri M, Magder LS. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort. Arthritis Rheumatol 2018; 70: 1790-5. DOI: https://doi.org/10.1002/art.40571
van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 2021; 8: e000538. DOI: https://doi.org/10.1136/lupus-2021-000538corr1
Tsang-A-Sjoe MWP, Bultink IEM, Heslinga M, Voskuyl AE. Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology 2017; 56: 121-8. DOI: https://doi.org/10.1093/rheumatology/kew377
Ugarte-Gil MF, Hanly J, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, et al. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis 2022; 81: 1541-8. DOI: https://doi.org/10.1136/ard-2022-222487
Emamikia S, Oon S, Gomez A, Lindblom J, Borg A, Enman Y, et al. Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. Rheumatology 2022; 61: 4752-62. DOI: https://doi.org/10.1093/rheumatology/keac185
Chan J, Walters GD, Puri P, Jiang SH. Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE). BMC Rheumatol 2023; 7: 37. DOI: https://doi.org/10.1186/s41927-023-00358-3
Apostolopoulos D, Morand EF. It hasn’t gone away: the problem of glucocorticoid use in lupus remains. Rheumatology 2017; 56: i114-22. DOI: https://doi.org/10.1093/rheumatology/kew406
Fasano S, Milone A, Nicoletti GF, Isenberg DA, Ciccia F. Precision medicine in systemic lupus erythematosus. Nat Rev Rheumatol 2023; 19: 331-42. DOI: https://doi.org/10.1038/s41584-023-00948-y
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 736-45. DOI: https://doi.org/10.1136/annrheumdis-2019-215089
Felten R, Scherlinger M, Mertz P, Chasset F, Arnaud L. New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review. Joint Bone Spine 2023; 90: 105523. DOI: https://doi.org/10.1016/j.jbspin.2023.105523
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31. DOI: https://doi.org/10.1016/S0140-6736(10)61354-2
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30. DOI: https://doi.org/10.1002/art.30613
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020; 382: 211-21. DOI: https://doi.org/10.1056/NEJMoa1912196
Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017; 69: 376-86. DOI: https://doi.org/10.1002/art.39962
Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 2019; 1: e208-19. DOI: https://doi.org/10.1016/S2665-9913(19)30076-1
Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol 2023; 75: 253-65. DOI: https://doi.org/10.1002/art.42392
Hitt E. Belimumab earns FDA approval for lupus. Available from: https://www.medscape.com/viewarticle/738729.
Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, et al. Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real-life setting. Arthritis Rheumatol 2020; 72: 1314-24. DOI: https://doi.org/10.1002/art.41253
Zen M, Gatto M, Depascale R, Regola F, Fredi M, Andreoli L, et al. Early and late response and glucocorticoid-sparing effect of belimumab in patients with systemic lupus erythematosus with joint and skin manifestations: results from the belimumab in real life setting study-joint and skin (BeRLiSS-JS). J Pers Med 2023; 13: 691. DOI: https://doi.org/10.3390/jpm13040691
Hammam N, Evans M, Bell CF, Gairy K, Yazdany J, Schmajuk G. Evaluating the use of glucocorticoids among belimumab‐treated patients with systemic lupus erythematosus in real‐world settings using the rheumatology informatics system for effectiveness registry. ACR Open Rheumatol 2022; 4: 883-9. DOI: https://doi.org/10.1002/acr2.11482
Costenbader K, Abe Y, Anaud L, Bertsias G, Fox NL, Gibb M, et al. Reduction in glucocorticoid use in patients with systemic lupus erythematosus treated with belimumab: a large pooled analysis of 5 placebo-controlled studies [abstract]. Arthritis Rheumatol 2021; 73.
Collins CE, Dall’Era M, Kan H, Macahilig C, Molta C, Koscielny V, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med 2016; 3: e000118. DOI: https://doi.org/10.1136/lupus-2015-000118
van Vollenhoven RF, Petri M, Wallace DJ, Roth DA, Molta CT, Hammer AE, et al. Cumulative corticosteroid dose over fifty-two weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials. Arthritis Rheumatol 2016; 68: 2184-92. DOI: https://doi.org/10.1002/art.39682
Cortés-Hernández J, Marras Fernández-Cid C, Andreu Sánchez JL, Calvo Alén J, García-Aparicio AM, Díez Álvarez E, et al. Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study. Reumatol Clin 2023; 19: 312-8. DOI: https://doi.org/10.1016/j.reuma.2022.08.001
Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, et al. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study. Rheumatol Int 2017; 37: 865-73. DOI: https://doi.org/10.1007/s00296-017-3682-9
AIFA. Determina 20 marzo 2023. Avaialble from: https://www.aifa.gov.it/documents/20142/961234/Determina_221-2023_Saphnelo.pdf. [Material in Italian].
AIFA. Determina 7 ottobre 2021. Available from: https://www.aifa.gov.it/documents/20142/961234/Determina_1213-2021_Benlysta.pdf. [Material in Italian].
EMA. Annex I. Summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/saphnelo-epar-product-information_en.pdf.
EMA. Annex I. Summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/benlysta-epar-product-information_en.pdf%20Last%20access%20March%206.
FDA. Benlysta. Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761043s021lbl.pdf.
FDA. Saphnelo. Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761123s000lbl.pdf.
Hembre BSH, Chokshi M, Hoffman SJ, Suleman F, Andresen S, Sandberg K, et al. States, global power and access to medicines: a comparative case study of China, India and the United States. 2000-2019. Global Health 2025; 21: 3. DOI: https://doi.org/10.1186/s12992-024-01092-2
Gross A. China market access for drugs is tougher, but some daylight too. Available from: https://www.pacificbridgemedical.com/uncategorized/china-market-access-for-drugs-is-tougher-but-some-daylight-too/.
Conti F, Ceccarelli F, Perricone C, Miranda F, Truglia S, Massaro L, et al. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. PLoS One 2012; 7: e45934. DOI: https://doi.org/10.1371/journal.pone.0045934
Inês L, Duarte C, Silva RS, Teixeira AS, Fonseca FP, da Silva JA. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study. Rheumatology 2014; 53: 85-9. DOI: https://doi.org/10.1093/rheumatology/ket322
Nikpour M, Urowitz MB, Ibañez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1152-8. DOI: https://doi.org/10.1002/art.24741
Morand EF, Vollenhoven RV, Furie R, Golder V, Tummala R. Op0051 Lupus low disease activity state attainment in the phase 3 placebo-controlled tulip long-term extension trial of anifrolumab. Ann Rheum Dis 2023; 82: 33-4. DOI: https://doi.org/10.1136/annrheumdis-2023-eular.1568
Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 2014; 41: 300-9. DOI: https://doi.org/10.3899/jrheum.121368
Bruce IN, van Vollenhoven RF, Psachoulia K, Lindholm C, Maho E, Tummala R, et al. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials. Lupus Sci Med 2023; 10: e000761. DOI: https://doi.org/10.1136/lupus-2022-000761
Sbeih N, Mathian A, Pineton de Chambrun M, Lhote R, Zahr N, Pha M, et al. Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter. Ann Rheum Dis 2020; 79: e148. DOI: https://doi.org/10.1136/annrheumdis-2019-215732
Altabás-González I, Pego-Reigosa JM, Mouriño C, Jiménez N, Hernández-Martín A, Casafont-Solé I, et al. Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients. Rheumatology 2025; 64: 276-82. DOI: https://doi.org/10.1093/rheumatology/kead696
Morand EF, Abreu G, Furie RA, Golder V, Tummala R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis 2023; 82: 639-45. DOI: https://doi.org/10.1136/ard-2022-222748
Floris A, Piga M, Perra D, Chessa E, Congia M, Mathieu A, et al. Treatment target in newly diagnosed systemic lupus erythematosus: the association of lupus low disease activity state and remission with lower accrual of early damage. Arthritis Care Res 2020; 72: 1794-9. DOI: https://doi.org/10.1002/acr.24086
Zucchi D, Tani C, Trentin F, Signorini V, Stagnaro C, Carli L, et al. POS1483 Is early remission a predictive factor for steroid-free remission in systemic lupus erithematosus? A real-life experience from a monocentric cohort. Ann Rheum Dis 2023; 82: 1097-8. DOI: https://doi.org/10.1136/annrheumdis-2023-eular.2918
Miyazaki Y, Funada M, Nakayamada S, Sonomoto K, Tanaka H, Hanami K, et al. Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry. Rheumatology 2024; 63: 2345-54. DOI: https://doi.org/10.1093/rheumatology/kead568
Tselios K, Gladman DD, Touma Z, Su J, Anderson N. Disease course patterns in systemic lupus erythematosus. Lupus 2019; 28: 114-22. DOI: https://doi.org/10.1177/0961203318817132
Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019; 393: 2344-58. DOI: https://doi.org/10.1016/S0140-6736(19)30546-X
Muanda FT, Blake PG, Weir MA, Ahmadi F, McArthur E, Sontrop JM, et al. Low-dose methotrexate and serious adverse events among older adults with chronic kidney disease. JAMA Network Open 2023; 6: e2345132. DOI: https://doi.org/10.1001/jamanetworkopen.2023.45132
Leaviss J, Carroll C, Essat M, van der Windt D, Grainge MJ, Card T, et al. Prognostic factors for liver, blood and kidney adverse events from glucocorticoid sparing immune-suppressing drugs in immune-mediated inflammatory diseases: a prognostic systematic review. RMD Open 2024; 10: e003588. DOI: https://doi.org/10.1136/rmdopen-2023-003588
Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol 2019; 71: 1125-34. DOI: https://doi.org/10.1002/art.40861
Santacruz JC, Mantilla MJ, Rueda I, Pulido S, Rodriguez-Salas G, Londono J. A practical perspective of the hematologic manifestations of systemic lupus erythematosus. Cureus 2022; 14: e22938. DOI: https://doi.org/10.7759/cureus.22938
Fayyaz A, Igoe A, Kurien BT, Danda D, James JA, Stafford HA, et al. Haematological manifestations of lupus. Lupus Sci Med 2015; 2: e000078. DOI: https://doi.org/10.1136/lupus-2014-000078
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 1151-9. DOI: https://doi.org/10.1136/annrheumdis-2018-214819
Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012; 71: 1833-8. DOI: https://doi.org/10.1136/annrheumdis-2011-200831
Casey KA, Guo X, Smith MA, Wang S, Sinibaldi D, Sanjuan MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med 2018; 5: e000286. DOI: https://doi.org/10.1136/lupus-2018-000286
Dong J, Zhao L, Pan L, Wang H, Wang L. Belimumab therapy for refractory immune thrombocytopenia in systemic lupus erythematosus patients with anti-phospholipid antibodies. Scand J Rheumatol 2024; 53: 59-62. DOI: https://doi.org/10.1080/03009742.2023.2247881
Nakayama K, Tamimoto Y, Nakayama T. Successful treatment with belimumab for immune thrombocytopenia associated with systemic lupus erythematosus: a report of two cases. Mod Rheumatol Case Rep 2023; 8: 69-73. DOI: https://doi.org/10.1093/mrcr/rxad055
Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin 2002; 20: 373-85. DOI: https://doi.org/10.1016/S0733-8635(02)00016-5
Werth VP. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev 2005; 4: 296-302. DOI: https://doi.org/10.1016/j.autrev.2005.01.003
Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol 2013; 27: 391-404. DOI: https://doi.org/10.1016/j.berh.2013.07.008
Cohen MR, Crosby D. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. J Rheumatol 1994; 21: 1665-9.
Sarkar MK, Hile GA, Tsoi LC, Xing X, Liu J, Liang Y, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis 2018; 77: 1653-64. DOI: https://doi.org/10.1136/annrheumdis-2018-213197
Stannard JN, Reed TJ, Myers E, Lowe L, Sarkar MK, Xing X, et al. Lupus skin is primed for IL-6 inflammatory responses through a keratinocyte-mediated autocrine type I interferon loop. J Invest Dermatol 2017; 137: 115-22. DOI: https://doi.org/10.1016/j.jid.2016.09.008
Psarras A, Alase A, Antanaviciute A, Carr IM, Md Yusof MY, Wittmann M, et al. Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. Nat Commun 2020; 11: 6149. DOI: https://doi.org/10.1038/s41467-020-19918-z
Niebel D, de Vos L, Fetter T, Brägelmann C, Wenzel J. Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions. Am J Clin Dermatol 2023; 24: 521-40. DOI: https://doi.org/10.1007/s40257-023-00774-8
Deeks ED. Anifrolumab: first approval. Drugs 2021; 81: 1795-802. DOI: https://doi.org/10.1007/s40265-021-01604-z
Morand EF, Furie RA, Bruce IN, Vital EM, Dall'Era M, Maho E, et al. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatol 2022; 4: e282-92. DOI: https://doi.org/10.1016/S2665-9913(21)00317-9
Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis 2022; 81: 951-61. DOI: https://doi.org/10.1136/annrheumdis-2021-221425
Blum FR, Sampath AJ, Foulke GT. Anifrolumab for treatment of refractory cutaneous lupus erythematosus. Clin Exp Dermatol 2022; 47: 1998-2001. DOI: https://doi.org/10.1111/ced.15335
Shaw K, Sanchez-Melendez S, Taylor D, Barker J, LaChance A, Shahriari N, et al. Assessment of clinical response to anifrolumab in patients with refractory discoid lupus erythematosus. JAMA Dermatol 2023; 159: 560-3. DOI: https://doi.org/10.1001/jamadermatol.2023.0175
Carter LM, Wigston Z, Laws P, Vital EM. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Br J Dermatol 2023; 189: 210-8. DOI: https://doi.org/10.1093/bjd/ljad089
Bao A, Petri MA, Fava A, Kang J. Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE. Lupus Sci Med 2023; 10: e001007. DOI: https://doi.org/10.1136/lupus-2023-001007
Khan MA, Khan FH, Khan HB, Saadeh C, Davey N. Role of anifrolumab in refractory cutaneous manifestations of lupus erythematosus: a case series and literature review. Cureus 2023; 15: e39553. DOI: https://doi.org/10.7759/cureus.39553
Plüß M, Piantoni S, Wincup C, Korsten P. Rapid response of refractory systemic lupus erythematosus skin manifestations to anifrolumab-a case-based review of clinical trial data suggesting a domain-based therapeutic approach. J Clin Med 2022; 11: 3449. DOI: https://doi.org/10.3390/jcm11123449
Ceccarelli F, Govoni M, Piga M, Cassone G, Cantatore FP, Olivieri G, et al. Arthritis in systemic lupus erythematosus: from 2022 International GISEA/OEG Symposium. J Clin Med 2022; 11: 6016. DOI: https://doi.org/10.3390/jcm11206016
Shumilova A, Vital EM. Musculoskeletal manifestations of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2023; 37: 101859. DOI: https://doi.org/10.1016/j.berh.2023.101859
Piga M, Congia M, Gabba A, Figus F, Floris A, Mathieu A, et al. Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus. Lupus 2018; 27: 190-8. DOI: https://doi.org/10.1177/0961203317716319
Piga M, Gabba A, Congia M, Figus F, Cauli A, Mathieu A. Predictors of musculoskeletal flares and Jaccoud׳s arthropathy in patients with systemic lupus erythematosus: a 5-year prospective study. Semin Arthritis Rheum 2016; 46: 217-24. DOI: https://doi.org/10.1016/j.semarthrit.2016.04.005
Mosca M, Tani C, Carli L, Vagnani S, Possemato N, Delle Sedie A, et al. The role of imaging in the evaluation of joint involvement in 102 consecutive patients with systemic lupus erythematosus. Autoimmun Rev 2015; 14: 10-5. DOI: https://doi.org/10.1016/j.autrev.2014.08.007
Gabba A, Piga M, Vacca A, Porru G, Garau P, Cauli A, et al. Joint and tendon involvement in systemic lupus erythematosus: an ultrasound study of hands and wrists in 108 patients. Rheumatology 2012; 51: 2278-85. DOI: https://doi.org/10.1093/rheumatology/kes226
Sandler RD, Vital EM, Mahmoud K, Prabu A, Riddell C, Teh LS, et al. Revision to the musculoskeletal domain of the BILAG-2004 index to incorporate ultrasound findings. Rheumatology 2024; 63: 498-505. DOI: https://doi.org/10.1093/rheumatology/kead241
Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. Lancet 2024; 403: 2326-38. DOI: https://doi.org/10.1016/S0140-6736(24)00398-2
Mehta B, Luo Y, Xu J, Sammaritano L, Salmon J, Lockshin M, et al. Trends in maternal and fetal outcomes among pregnant women with systemic lupus erythematosus in the United States: a cross-sectional analysis. Ann Intern Med 2019; 171: 164-71. DOI: https://doi.org/10.7326/M19-0120
Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; 76: 476-85. DOI: https://doi.org/10.1136/annrheumdis-2016-209770
ISS. La salute riproduttiva nei pazienti con malattie reumatologiche. Available from: https://www.iss.it/it/web/guest/-/salute-riproduttiva-in-pazienti-con-malattie-reumatologiche.
Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology Guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 2020; 72: 529-56. DOI: https://doi.org/10.1002/art.41191
Russell MD, Dey M, Flint J, Davie P, Allen A, Crossley A, et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology 2023; 62: e48-88. DOI: https://doi.org/10.1093/rheumatology/keac686
Nakai T, Honda N, Soga E, Fukui S, Kitada A, Yokogawa N, et al. Effect of remission, clinical remission with active serology, and glucocorticoid dosage on the pregnancy outcome of pregnant patients with systemic lupus erythematosus. Arthritis Res Ther 2024; 26: 63. DOI: https://doi.org/10.1186/s13075-024-03298-6
Ponticelli C, Moroni G. Immunosuppression in pregnant women with systemic lupus erythematosus. Expert Rev Clin Immunol 2015; 11: 549-52. DOI: https://doi.org/10.1586/1744666X.2015.1033404
Pofi R, Tomlinson JW. Glucocorticoids in pregnancy. Obstet Med 2020; 13: 62-9. DOI: https://doi.org/10.1177/1753495X19847832
Shimada H, Wakiya R, Kanenishi K, Miyatake N, Nakashima S, Mansour MMF, et al. Preterm birth is strongly affected by the glucocorticoid dose during pregnancy in women complicated by systemic lupus erythematosus. Arthritis Res Ther 2022; 24: 10. DOI: https://doi.org/10.1186/s13075-021-02699-1
Balevic S, Sims CA, Eudy A, Smith V, Clowse M. Azathioprine metabolite levels and outcomes during pregnancies with rheumatic disease. Lupus Sci Med 2024; 11: e001036. DOI: https://doi.org/10.1136/lupus-2023-001036
Jiang Y, Tao M, Chen J, Luo L, You Q, Wu H, Zhang N. Calcineurin inhibitors in the treatment of systemic lupus erythematosus during pregnancy: a narrative review with emphasis on efficacy and safety. Eur J Obstet Gynecol Reprod Biol 2024; 294: 148-55. DOI: https://doi.org/10.1016/j.ejogrb.2023.12.039
Nakai T, Honda N, Soga E, Fukui S, Kitada A, Yokogawa N, et al. A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration during pregnancy in women with systemic lupus erythematosus: study from two Japanese tertiary referral centers. Arthritis Res Ther 2024; 26: 15. DOI: https://doi.org/10.1186/s13075-023-03256-8
Lateef A, Petri M. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol 2013; 27: 435-47. DOI: https://doi.org/10.1016/j.berh.2013.07.005
Zen M, Saccon F, Gatto M, Montesso G, Larosa M, Benvenuti F, et al. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. Rheumatology 2020; 59: 1591-8. DOI: https://doi.org/10.1093/rheumatology/kez422
Björk M, Dahlström Ö, Wetterö J, Sjöwall C. Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. BMC Musculoskelet Disord 2015; 16: 188. DOI: https://doi.org/10.1186/s12891-015-0621-3
Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology 2009; 48: 673-5. DOI: https://doi.org/10.1093/rheumatology/kep062
Tani C, Zucchi D, Haase I, Larosa M, Crisafulli F, Strigini FAL, et al. Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study. Rheumatology 2021; 60: 5610-9. DOI: https://doi.org/10.1093/rheumatology/keab155
Saccon F, Zen M, Gatto M, Margiotta DPE, Afeltra A, Ceccarelli F, et al. Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. Ann Rheum Dis 2020; 79: 943-50. DOI: https://doi.org/10.1136/annrheumdis-2020-217070
Zen M, Iaccarino L, Gatto M, Saccon F, Larosa M, Ghirardello A, et al. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 2018; 77: 104-10. DOI: https://doi.org/10.1136/annrheumdis-2017-211613
Roccatello D, Sciascia S, Rossi D, Fenoglio R. Refractory systemic lupus erythematosus: identification and pharmacological management. Drugs 2023; 83: 117-34. DOI: https://doi.org/10.1007/s40265-022-01824-x
Gomez A, Qiu V, Cederlund A, Borg A, Lindblom J, Emamikia S, et al. Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus. Front Med 2021; 8: 651249. DOI: https://doi.org/10.3389/fmed.2021.651249
Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 2016; 25: 727-34. DOI: https://doi.org/10.1177/0961203315627202
EMA. Saphnelo. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/saphnelo.
Morand EF, Trasieva T, Berglind A, Illei GG, Tummala R. Lupus low disease activity state (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab. Ann Rheum Dis 2018; 77: 706-13. DOI: https://doi.org/10.1136/annrheumdis-2017-212504
Kalunian K, Dall’Era M, Furie R, Psachoulia K, Maho E, Lindholm C, et al. Anifrolumab results in favorable responses regardless of SLE disease duration: post hoc analysis of data from 2 Phase 3 trials [abstract]. 2021; 73 (suppl 9). Accessed March 26, 2024. Arthritis Rheumatol 2021; 73: 1741.
113. Manzi S, Furie R, Morand E, Abreu G, Lindholm C, Raj Tummala R. SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials. Arthritis Rheumatol 2021; 73: 1739.
Maffi M, Tani C, Cascarano G, Scagnellato L, Elefante E, Stagnaro C, et al. Which extra-renal flare is ‘difficult to treat’ in systemic lupus erythematosus? A one-year longitudinal study comparing traditional and machine learning approaches. Rheumatology 2024; 63: 376-84. DOI: https://doi.org/10.1093/rheumatology/kead166
Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, et al. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Ann Rheum Dis 2024; 83: 464-74. DOI: https://doi.org/10.1136/ard-2023-224919
Kuhn A, Herrmann M, Kleber S, Beckmann-Welle M, Fehsel K, Martin-Villalba A, et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 2006; 54: 939-50. DOI: https://doi.org/10.1002/art.21658
Scholtissek B, Zahn S, Maier J, Klaeschen S, Braegelmann C, Hoelzel M, et al. Immunostimulatory endogenous nucleic acids drive the lesional inflammation in cutaneous lupus erythematosus. J Invest Dermatol 2017; 137: 1484-92. DOI: https://doi.org/10.1016/j.jid.2017.03.018
Billi AC, Ma F, Plazyo O, Gharaee-Kermani M, Wasikowski R, Hile GA, et al. Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. Sci Transl Med 2022; 14: eabn2263. DOI: https://doi.org/10.1126/scitranslmed.abn2263
Grassi M, Capello F, Bertolino L, Seia Z, Pippione M. Identification of granzyme B-expressing CD-8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis. Clin Exp Dermatol 2009; 34: 910-14. DOI: https://doi.org/10.1111/j.1365-2230.2009.03297.x
Wenzel J, Uerlich M, Wörrenkämper E, Freutel S, Bieber T, Tüting T. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol 2005; 153: 1011-5. DOI: https://doi.org/10.1111/j.1365-2133.2005.06784.x
Kiefer K, Oropallo MA, Cancro MP, Marshak-Rothstein A. Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol 2012; 90: 498-504. DOI: https://doi.org/10.1038/icb.2012.10
Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002; 123: 141-51. DOI: https://doi.org/10.1053/gast.2002.34175
Ntali S, Nikolopoulos D, Pantazi L, Emmanouilidou E, Papagoras C, Fanouriakis A, et al. Remission or low disease activity at pregnancy onset are linked to improved foetal outcomes in women with systemic lupus erythematosus: results from a prospective observational study. Clin Exp Rheumatol 2022; 40: 1769-78. DOI: https://doi.org/10.55563/clinexprheumatol/g4rby6
Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen YH, Cho J, Lateef A, et al. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study. Lancet Rheumatol 2022; 4: e822-30. DOI: https://doi.org/10.1016/S2665-9913(22)00304-6
Frodlund M, Jönsen A, Remkus L, Telg G, Söderdahl F, Leonard D. Glucocorticoid treatment in SLE is associated with infections, comorbidities and mortality—a national cohort study. Rheumatology 2024; 63: 1104-12. DOI: https://doi.org/10.1093/rheumatology/kead348
Zen M, Iaccarino L, Gatto M, Bettio S, Saccon F, Ghirardello A, et al. The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. Ann Rheum Dis 2017; 76: 562-5. DOI: https://doi.org/10.1136/annrheumdis-2016-210154
Floris A, Chessa E, Sebastiani GD, Prevete I, Iannone F, Coladonato L, et al. Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study. RMD Open 2022; 8: e002701. DOI: https://doi.org/10.1136/rmdopen-2022-002701
Zen M, Iaccarino L, Gatto M, Bettio S, Nalotto L, Ghirardello A, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 2015; 74: 2117-22. DOI: https://doi.org/10.1136/annrheumdis-2015-207347
Urowitz MB, Feletar M, Bruce IN, Ibañez D, Gladman DD. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005; 32: 1467-72.
Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 2022; 81: 496-506. DOI: https://doi.org/10.1136/annrheumdis-2021-221478
Furie R, Morand EF, Askanase AD, Vital EM, Merrill JT, Kalyani RN, et al. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus 2021; 30: 1254-63. DOI: https://doi.org/10.1177/09612033211014267
How to Cite
The role of anifrolumab in reshaping the treatment landscape of extra-renal systemic lupus erythematosus. (2025). Reumatismo. https://doi.org/10.4081/reumatismo.2025.1830
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
